Abstract. Aberrant methylation of gene promoters and corresponding loss of gene expression plays a critical role in the initiation and progression of colorectal cancer. An IL-6-type cytokine receptor, leukemia inhibitory factor receptor (LIFR), is a component of cell-surface receptor complexes for multifunctional cytokines such as LIF. Herein, we report that LIFR is methylated in human colon cancer. LIFR promoter was methylated in primary tumor tissues with high frequency (65%, 52/80). Quantitative methylation-specific PCR (TaqMan-MSP) demonstrated differential promoter methylation of LIFR in primary colorectal cancer tissues as compared to normal colon tissues (5%, 4/80). LIFR methylation was not detectable in 13 normal colon mucosa samples obtained from patients without cancer. The mRNA expression of LIFR was significantly down-regulated in colon cancer tissues as compared to corresponding normal tissues. A strong expression of LIFR protein was observed in all non-malignant normal and adjacent normal colon mucosa tissues whereas down-regulated LIFR protein expression was observed in primary tumors. These results demonstrate that cancer-specific methylation and a specific decrease of LIFR expression are a common inactivation event in colon cancer development.

Introduction

In addition to genetic mutations of oncogenes and TSGs, carcinogenic progression from benign neoplasm to adenocarcinoma can occur through epigenetic changes in gene promoters (1). Epigenetic alterations have been widely recognized to play an important role in the development of cancer. Aberrant methylation of gene promoters and corresponding loss of gene expression play a critical role in the initiation and progression of colorectal cancer (CRC), and have been recognized as one of the hallmarks of cancer (2). Knowledge of methylation patterns across the genome can help to identify key genes inactivated during tumor formation. Genes that display cancer-specific methylation may serve as biomarkers for early detection, diagnosis and prognosis of cancer (3-6). Genes commonly hypermethylated in CRC include \textit{hMLH1}, \textit{p16\textsuperscript{INK4a}}, \textit{RAR-\beta}, \textit{APC}, \textit{MGMT}, \textit{cyclin A1}, \textit{COX-2} and \textit{WT-1} (7-9).

The IL-6 cytokines, including IL-6, leukemia inhibitory factor (LIF), and oncostatin M (OSM), cooperate with a variety of inflammatory cytokines, and play an important role in the local inflammatory process and in the systemic acute phase reaction. IL-6 cytokines have also been implicated in early embryonic development, differentiation as well as tumor growth (10-16). The ability of a cell type to respond to IL-6 cytokines is determined by the expression pattern of the receptor subunit genes (17,18). The leukemia inhibitory factor receptor (LIFR) subunit is a component of cell-surface receptor complexes for the multifunctional cytokines, LIF, cardiotrophin-1, ciliary neurotrophic factor, and human OSM (19). LIF signaling through a receptor heterodimer of LIFR and gp130 induces tyrosine phosphorylation of STAT3 leading to target gene expression (20), and inhibits proliferation of cancer cell lines (18) and non-malignant human breast epithelial cells which express gp130, LIFR and the oncostatin M-specific receptor (OSMR) (21). Recently, suppression of LIFR expression and modification of cellular responsiveness to LIF by epigenetic alterations was reported. Treatment with FR901228, an HDAC inhibitor, induced LIFR transcription in cells that did not express LIFR, and increased the responsiveness to LIF in various cell types, including non-malignant normal and tumor cell lines (22). Interestingly, reduced expression and altered DNA methylation of LIFR was reported in the H-35 rat hepatoma cell line. These cells displayed greatly reduced LIF responsiveness, but when treated with an inhibitor of DNA methyltransferase, 5-Aza-2'-
deoxycytidine (5-Aza-dC), displayed increased cellular sensitivity to LIF (23). Epigenetic control of LIFR expression was also observed in human lung cancer and hepatocellular carcinoma cells (24,25). However, little is known about the epigenetic regulation of LIFR in human colon cancer.

We previously reported that LIFR was expressed in a non-tumorogenic human embryonic kidney cell line, HEK293, and HCT116 colon cancer cells, but silenced in most CRC cell lines tested, whereas glp130, the heterodimer of both OSMR and LIFR, was ubiquitously expressed in all the cell lines tested (26). In this report, we examined the methylation status of LIFR gene promoter in human colon cancer. LIFR was frequently methylated in primary CRC tissues but at minimal levels in corresponding normal tissues. A specific decrease of LIFR mRNA and protein in colon cancer was also observed.

Materials and methods

Cell lines and tissues. CRC cell lines were purchased from ATCC (Manassas, VA). CRC cell lines were grown in 5X McCoy medium supplemented with 10% FBS. HEK293 cells were grown in DMEM with 10% FBS. Eighty pairs of DNA from primary colorectal cancers (PT) and matched normal colon mucosa (PN) were described previously (27). Thirteen normal colon epithelial tissues (NN) were obtained from patients without cancer from the Department of Pathology, The Johns Hopkins University. Nine pairs of gDNA used for MSP analysis in this study were from Istanbul University, Turkey.

Bisulfite-sequencing. Bisulfite-modified genomic DNA was amplified by PCR as described previously (28). Primers for the 1st CpG island were 5'-TTATGATTTTTTGAGAGCG-G3' (LIFR Bi-R), 5'-CGCCTTTCTCTCCCCCC-G3' (LIFR Bi-R). Primers for the 2nd CpG island were 5'-TTTGTGGATTATTGTGATATAATTTTGAGAGCGG-G3' (LIFR 2nd Bi-F) 5'-TACCTAAACACCCCCCCAACC-3' (LIFR 2nd Bi-R). The criteria to determine methylation by bisulfite-sequencing was followed as described previously (26).

Methylation-specific PCR (MSP). Bisulfite-treated DNA was amplified with either methylation-specific or un-methylation-specific primers described previously (26). Primers sequences are 5'-TTTTATGATTTTTTGAGAGCGG-G3' (LIFR M-SP-F), 5'-CCCCTTCTCTCCCCCC-G3' (LIFR M-SP-R), 5'-TTTTATGATTTTTTGAGAGCGG-G3' (LIFR UnM-SP-F), and 5'-CCCCTTCTCTCCCCCC-G3' (LIFR UnM-SP-R). Lymphocyte DNA from a healthy individual was methylated in vitro with excess SssI methyltransferase (New England Biolabs Inc., Beverly, MA) to generate completely methylated DNA, and 9 ng of the DNA after bisulfite treatment was used as a positive control for MSP.

Quantitative methylation-specific PCR (TaqMan-MSP). Quantitative methylation analysis was performed as described (26). LIFR M-SP-F and LIFR M-SP-R primers were used for TaqMan-MSq and the probe sequence was 5'-FAM-GGCCATCGTCTTACCAACCAAGGATAG-G3'. The methylation ratio (TaqMan methylation value, TaqMeth V) was defined as the quantity of fluorescence intensity derived from promoter amplification of LIFR divided by fluorescence intensity from β-actin amplification, and multiplied by 100.

5-Aza-dC treatment and RT-PCR. Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) and/or trichostatin A (TSA), and RNA extraction and cDNA synthesis were followed as described (28). Primer sequences for RT-PCR were as previously reported (29). To determine quantitation of gene expression, the real-time RT-PCR was performed as described (26). Primer sequences for real-time RT-PCR are 5'-TTATGATTTTTTGAGAGCGG-TGACAAAGGAAAA-3' (LIFR reaIT-F), 5'-TGGATTGAGAGCGG-3' (LIFR reaIT-R). Five matched normal and tumor cDNA (a-e) were purchased from Clontech Laboratories, Inc. (Mountain View, CA), and cDNA from a patient without cancer and from an CRC patient were purchased from BioChain Institute, Inc. (Hayward, CA).

Immunohistochemistry. Tissue microarrays were performed with sections (5 μm) of colon cancer tissues, adjacent tissues 1.5 cm away from tumor, and non-malignant normal colon tissues which were purchased from US Biomax, Inc. (Rockville, MD), and IHC was performed as described (26) with anti-LIFR rabbit polyclonal antibody (1:100 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA).

Statistical analysis. We used gene methylation levels (TaqMeth V) to construct a receiver operating characteristic (ROC) curve for the detection of colon cancer as described (26).

Results

LIFR is methylated in CRC cell lines and primary CRC tissues. To investigate promoter methylation of LIFR, we searched CpG islands in the LIFR promoter within 5 kb upstream and 5 kb downstream of the transcription start site (TSS) by Methprimer. We found two CpG islands in the LIFR promoter that closely reside at -458 ~ +526 bp (1st CpG island) and -691 ~ -465 (2nd CpG island) with high GC density (50-90%) (Fig. 1A). Two pairs of sequencing primers were designed in the 1st region from -253 bp to +65 bp that harbors a total of 50 CpGs, and in the 2nd region from -843 to -546 bp where 19 CpGs reside. MSP primers were designed at the region from -255 to +54 bp in the 1st CpG island, and a probe (P) for TaqMan-MSP was designed within this region.

LIFR methylation status was examined in CRC cell lines and HEK293 cells by bisulfite-sequencing as a pilot study. In the 1st region, HCT116 cells harbored methylated only in one of 50 CpGs, whereas Widr and SW480 cells harbored methylation in 47 of 50 CpGs. In the 2nd region, HEK293 cells harbored no CpG methylated of the LIFR promoter. In contrast, all CRC cell lines examined harbored complete methylation in all 19 CpGs in the 2nd region. Representative sequencing results are shown in Fig. 1B.

We then performed MSP in the cell lines and two normal colon mucosa tissues collected from CRC patients (PN1 and PN2). PCR-amplification with methylation-specific primers (M-SP) was clearly seen in SW480, LDL1, HT29, Widr, SW48, and RKO cells, whereas no methylated DNA was detected in HCT116, HEK293 cells and two normal colon mucosa tissues (Fig. 2A). Consistent with the results of bisulfite-sequencing,
un-methylated DNA was seen in HCT116, HEK293 cells and in the two normal colon mucosa tissues. However, un-methylated DNA was not observed in the remaining 6 CRC cell line, indicating that HEK293 cells harbor only un-methylated LIFR at least at the two regions examined, and that CRC cell lines except for HCT116 cells harbor dense CpG methylation in the promoter (Fig. 2B). Methylation of the LIFR promoter was further investigated in 9 pairs of colon cancer (PT) and matched normal colon mucosa tissues (PN). Methylated DNA was not detected in the normal colon tissues, but clearly observed in 7 of 9 PT cases (77%) (Fig. 2C). Conversely, non-methylated DNA was observed in all 9 PN cases, but only in the two PT cases in which methylated DNA was not observed.

To quantify LIFR promoter methylation, real-time MSP analysis was performed in 80 pairs of colon normal tissues (PN) and primary CRC (PT) as well as 5 CRC cell lines (HCT116, DLD1, SW480, Widr and RKO). Thirteen colon normal mucosa tissues of the non-cancer patients (NN) were also included to compare methylation specificity between cancer and non-cancer patients. In 80 pairs of colon samples, methylation values (TaqMeth V) in tumor ranged from 0 to 390.03 (median value 56.25), and in normal colon from 0 to 181.94 (median value 0.00) (Fig. 3A). The overall TaqMeth V levels detected in primary CRC (50.40±67.21, mean ± SD) were also significantly higher than that in corresponding normal tissues (3.26±20.71, mean ± SD) (P<0.001) (Fig. 3B).

Methylation of LIFR yielded a highly discriminative receiver-operator characteristic (ROC) curve profile, clearly distinguishing CRC from corresponding normal mucosa (Fig. 3C). The optimal cut-off (value, 3.198) was calculated from the ROC analysis in order to maximize sensitivity and specificity. At this cut-off, the specificity was 95% (76/80) and sensitivity was 65% (52/80) (P<0.001, Fisher's exact test). Only 4 of 80 of matched normal colon mucosa displayed TaqMeth v over the cut-off. Only 1 (TaqMeth v = 0.4870) of 13 NN samples and 12 of 80 of PN displayed a TaqMeth v over 0.00. The methylation level in all remaining 12 cases of NN, 27 cases of PT, and 68 cases of PN was undetectable. A high level of LIFR promoter methylation was also found in DLD1, SW480, Widr and RKO cells, but LIFR methylation in HCT116 cells was not detected by TaqMan-MSP. In addition to a simple frequency, the comparison of methylation level of normal and tumor tissues from the same individual patients revealed that the majority of the tumor tissues harbored much
higher values than matched normal colon mucosa (Fig. 3D). Taken together, LIFR was frequently methylated in primary CRC tissues but at minimal levels in corresponding normal tissue.

**LIFR is down-regulated in colon cancer.** To investigate the mRNA expression of LIFR, RT-PCR analysis was performed. LIFR expression was observed only in the cells where methylation in the 1st region was not found (HCT116 and HEK293) (Fig. 4A) (26), indicating that methylation in the 1st CpG island is enough to silence LIFR gene expression. The expression of LIFR was much higher in HEK293 cells harboring no methylation in the 2nd region than HCT116 cells harboring a dense methylation at the region, implicating that the 2nd CpG island regulates a basal level of LIFR. The other 6 CRC cell lines that harbored LIFR methylation in both regions did not express the LIFR transcript (data not shown) (26). The silenced LIFR in SW480 and DLD1 was re-activated by the treatment of the de-methylating agent, 5-Aza-dC (5 μM), suggesting a tight correlation between promoter methylation and expression of the LIFR. The expression in HCT116 was also further increased by 5-Aza-dC treatment, indicating that the 2nd region of the LIFR promoter might be de-methylated by the treatment. To examine the expression of LIFR in human tissue, we performed RT-PCR in cDNA prepared from tumor (PT) and corresponding normal tissues (PN) of five individual colon cancer patients (matched cDNA). In 3 of 5 tumor cases, LIFR was down-regulated or not detectable (Fig. 4B). To quantify the expression level, we performed real-time RT-PCR in the same panel of cDNA samples. In 4 of 5 tumor cases, LIFR was significantly down-regulated (P=0.043, Wilcoxon matched-pairs signed-ranks test) (Fig. 4C, left). The expression of LIFR in tumor from a CRC patient was 28 times lower than in normal tissue (NN) from a patient without cancer (P<0.001, t-test) (Fig. 4C, right). By immunohistochemical staining of a colon normal and cancer tissue microarray with an anti-LIFR antibody, strong expression of LIFR was detected in all non-malignant normal tissues and adjacent normal colon mucosa from colon cancer.
Figure 3. Quantitative level of LIFR methylation. (A) A Scatter plot of LIFR methylation levels. Samples with a ratio equal to zero could not be plotted correctly on a log scale, so are presented here as 0.01. TaqMeth V is described in Materials and methods. Arrow, an optimal cut-off value for LIFR calculated from ROC analysis (3.198). (B) The overall TaqMeth V detected in primary CRC were significantly higher than that in corresponding normal tissues (P<0.001, Wilcoxon matched-pairs signed-ranks test). (C) ROC curve analysis of TaqMeth V of LIFR. The area under ROC (AUROC, 0.7928±0.032) conveys the accuracy in distinguishing matched normal colon (PN) from CRC (PT) in terms of its sensitivity and specificity (P<0.001). Solid line, LIFR; dash line, no discrimination. (D) Methylation levels of normal and tumor tissues in individual patients.

Figure 4. mRNA expression of LIFR in CRC. RT-PCR analysis in cell lines (A), and five pairs (a-e) of normal (N) and tumor cDNA (T) prepared from CRC patients (Pts) (B). NP, cDNA from normal placenta. (C) Real-time RT-PCR in the five pairs of cDNA (left). The LIFR expression between patients with colon cancer (T) or without cancer (NN) (right). Relative expression (fold) was calculated by comparing the ratios of mRNA expression of LIFR to an internal control gene, GAPDH. Experiments were done in duplicate, and values indicate means ± SD.
patients (Fig. 5). However, faint or only mild expression of LIFR was detected in 9 of 10 primary tumors (Table I). These results suggest a specific decrease of LIFR mRNA and protein in colon cancer development.

**Discussion**

Colorectal cancer (CRC) is the second leading cause of cancer in both men and women worldwide (30). At diagnosis, 19% of CRC cases are metastatic, and the overall 5-year survival rate for patients with metastatic CRC is less than 10% (30). Mortality rates for colon cancer have fallen during the past 20 years because of early detection from increased screening. However, more advanced knowledge of the molecular pathogenesis of CRC or key factors in CRC development is still needed. Finding potential diagnostic molecular markers for CRC would thus be invaluable for early detection and potentially treatment of CRC.

Epigenetic events play key roles in the development and progression of CRC, and aberrant DNA methylation of cancer-related genes is one of the major mechanisms in carcinogenesis leading to transcriptional silencing of tumor suppressor genes (31). DNA methylation in gene promoter is among the earliest and most frequent alterations, and occurs at various stages in colorectal neoplasia. A number of genes are commonly hypermethylated in CRC (7-9). However, genes methylated only in neoplastic tissues with high frequency are rare. Previously, we have reported aberrant methylation of OSMR (26), NMDAR2A (27) and DFNA5 (32) in CRC. Methylation of these genes was detected in more than 80% of primary CRC tissues.

In this study, we identified LIFR as a gene harboring cancer-specific promoter methylation in human colorectal cancer. The high frequency of LIFR methylation in CRC (65%) ranks with only a few other genes methylated at high frequency in CRC (Cyclin A1, CDX1, RAR-β, MYOD1, p15INK4b and COX-2) in a cancer-specific manner (8). A clear discrimination of tumor from normal tissues by TaqMan-MSP of the LIFR, indicating that detection of LIFR promoter methylation in blood or stool DNA may have potential for identifying individuals with cancer. Moreover, a strict correlation between promoter methylation and silencing of LIFR in CRC cell lines implies that promoter methylation of LIFR is one of the mechanisms of gene silencing in CRC.

Loss of LIFR expression has been reported in high Gleason grade carcinomas of the prostate (33), suggesting that LIFR silencing is important to predict increased malignancy in the early stages of cancer. In our results, the mRNA level of LIFR was down-regulated in 4 of 5 colon cancers, and silenced in CRC cell lines that harbored LIFR methylation. Down-regulation of LIFR protein in primary CRC tissues was observed by IHC analysis, but a correlation between decreased LIFR expression and tumor grades was not observed. However, it is still unknown if absence of LIFR may distinguish clinically significant cancers from simple tumors that are unlikely to progress to aggressive cancers. Future work will be focused on LIFR as a diagnostic biomarker for aggressive, metastatic colon cancer.

The interleukin-6 (IL-6)-type cytokines, OSM and LIF, have two specific heterodimeric signaling complexes; gp130/LIFR and gp130/OSMR (34). gp130/OSMR is activated only by OSM, but gp130/LIFR can be activated by either LIF, OSM or
both (17). The gp130/OSMR complex activates OSM-specific signaling pathways via the JNK/SAPk and Stat1/Stat5 pathways, whereas both gp130/LIFR and gp130/OSMR complexes activate Stat3 and erk as common signaling pathways (35). Previously, we reported decreased transcription of OSMR in CRC as well as a significant growth inhibition by OSM in OSMR-expressing HCT116 cells, which was reversed by gene knock-down of OSMR (26). However, the suppression of cell growth by OSM was not observed in SW480 and DLD-1 cells that did not express OSMR due to the promoter methylation of OSMR, whereas it was observed when 5-Aza-dC was treated in those cells. Interestingly, a correlation of LIFR down-regulation with reduced cell responsiveness to LIF has been reported. The H-35 cells that harbored DNA methylation and reduced expression of LIFR had a reduced LIF responsiveness, but exhibited an increased cellular sensitivity to LIF by 5-Aza-dC treatment (23). Treatment with FR901228 (FR), an HDAC inhibitor, induced LIFR transcription in various cell types that did not express LIFR, and increased the responsiveness to LIF (22). The FR-stimulated expression of IL-6-type cytokine receptors in tumor cells supports suppression of cell growth by utilizing the growth inhibitory effect of these cytokines (22). Thus, methylated OSMR and LIFR in CRC might decrease tumor-inhibiting signals from IL-6-type cytokines and key downstream signaling events.

It has been reported that LIF together with LIFR appear to form a more stable complex with gp130 than OSM with gp130/OSMR, and co-activation of LIFR and OSMR results in a predominant LIF-like response (36). These results indicate that a hierarchical order of cytokine receptor action exists in which LIFR ranks as a dominant member. Therefore, loss of LIFR expression by the promoter methylation might have more profound effects on the signaling pathways activated by the IL-6-type cytokines. Further study will be focused on a dominant role of LIFR on downstream signaling pathways contributing to CRC development.

In conclusion, we have demonstrated cancer-specific methylation of LIFR in human colon cancer. A correlation between promoter methylation and expression of LIFR implicates this gene as a common inactivation event in colon tumorigenesis. Inactivation of OSMR and LIFR by promoter methylation appears to constitute different nodal points for abrogation of IL-6 induced tumor suppression and thus identify a targeted therapeutic pathway. Due to its high frequency in primary tumors and near absence in normal tissues, detection and quantification of LIFR methylation thus deserves further attention as a diagnostic biomarker. Detection of LIFR methylation levels in stool and/or plasma DNA may prove valuable in the diagnosis and monitoring of patients with colon cancer.

Acknowledgements

This study was supported by National Cancer Institute (U01-CA84986) and the Flight Attendant Medical Research Institute (Myoung S. Kim) and Oncomethylome Sciences, SA. Under a licensing agreement between Oncomethylome Sciences, SA and the Johns Hopkins University, D. Sidransky is entitled to a share of royalty received by the University upon sales of any products described in this report. D. Sidransky owns Oncomethylome Sciences, SA stock, which is subject to certain restrictions under University policy. D. Sidransky is a paid consultant to Oncomethylome Sciences, SA and is a paid member of the company's Scientific Advisory board. The Johns Hopkins University in accordance with its conflict of interest policies is managing the terms of this agreement.

References


Table I. Immunohistochemical analysis of LIFR in colon cancer tissue microarray with normal tissue controls.

<table>
<thead>
<tr>
<th>Tissues</th>
<th>Expression</th>
<th>Tumor grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>++</td>
<td>III</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>III</td>
</tr>
<tr>
<td>3</td>
<td>++</td>
<td>III</td>
</tr>
<tr>
<td>4</td>
<td>++</td>
<td>III</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>II</td>
</tr>
<tr>
<td>6</td>
<td>++</td>
<td>II</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>I</td>
</tr>
<tr>
<td>8</td>
<td>+</td>
<td>I</td>
</tr>
<tr>
<td>9</td>
<td>+</td>
<td>I</td>
</tr>
<tr>
<td>10</td>
<td>+++</td>
<td>I</td>
</tr>
<tr>
<td>Non-malignant normal colon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>Cancer adjacent normal colon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>+++</td>
<td></td>
</tr>
</tbody>
</table>

Expression level is indicated as: +, faint; ++, mild; +++, moderate; ++++, strong.


